The Coats effect…
Lexicon Pharmaceuticals announces mid-stage pain fail, blames dosing choice – Endpoints News
https://endpts.com/lexicon-pharmaceuticals-announces-mid-stage-pain-fail-blames-dosing-choice/
Paul Schloesser
Associate Editor
A small Texas biotech is moving a pain candidate forward into late-stage clinical development, despite a Phase II fail.
Lexicon Pharmaceuticals — founded by Arthur Sands, now CEO of Nurix Therapeutics — told investors Wednesday that a Phase II proof-of-concept trial in postherpetic neuralgia failed to meet statistical significance.
LX9211, which targets AAK1, achieved a reduction in average daily pain score (ADPS) of 2.42 from baseline at week 6 compared to a reduction of 1.62 in the placebo arm. However, with a placebo adjusted difference of 0.80, the p-value of 0.12 made the trial and the data statistically insignificant. Significance is met if the p-value is at or below 0.05, which indicates a 95% chance that the results aren’t random.
Lexicon Pharmaceuticals announces mid-stage pain fail, blames dosing choice – Endpoints News
https://endpts.com/lexicon-pharmaceuticals-announces-mid-stage-pain-fail-blames-dosing-choice/
Paul Schloesser
Associate Editor
A small Texas biotech is moving a pain candidate forward into late-stage clinical development, despite a Phase II fail.
Lexicon Pharmaceuticals — founded by Arthur Sands, now CEO of Nurix Therapeutics — told investors Wednesday that a Phase II proof-of-concept trial in postherpetic neuralgia failed to meet statistical significance.
LX9211, which targets AAK1, achieved a reduction in average daily pain score (ADPS) of 2.42 from baseline at week 6 compared to a reduction of 1.62 in the placebo arm. However, with a placebo adjusted difference of 0.80, the p-value of 0.12 made the trial and the data statistically insignificant. Significance is met if the p-value is at or below 0.05, which indicates a 95% chance that the results aren’t random.